Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT02694770 is registered in ClinicalTrials.gov with AbGenomics B.V Taiwan Branch as lead sponsor.

NCT NCT02694770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02694770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
AbGenomics B.V Taiwan Branch
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2016
Completion date
February 28, 2018
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory agvhd subsequent to allogeneic hematopoietic cell transplantation